surinabant
structure in first source
Also Known As:
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide; SR 147778; SR-147778; SR147778
Networked: 6
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Aubin, Henri-Jean:
1 article
(07/2012)
|
2. | Tonstad, Serena:
1 article
(07/2012)
|
3. | Bermudez-Silva, F J:
1 article
(09/2008)
|
4. | McPartland, J M:
1 article
(09/2008)
|
5. | Viveros, M P:
1 article
(09/2008)
|
6. | de Fonseca, F Rodriguez:
1 article
(09/2008)
|
7. | Bermudez-Silva, Francisco Javier:
1 article
(01/2008)
|
8. | Gallego, Araceli:
1 article
(01/2008)
|
9. | Lamota, Laura:
1 article
(01/2008)
|
10. | Llorente, Ricardo:
1 article
(01/2008)
|
Related Diseases
1. | Alcoholism (Alcohol Abuse)
01/01/2022
- " In this review we summarize and compare Baclofen, Gabapentin, Topiramate, Ondansetron, Varenicline, Aripiprazole, Quetiapine, Clozapine, Antidepressants, Lithium, Neuropeptide Y, Neuropeptide S, Corticotropin-releasing factor antagonists, Oxytocin, PF-05190457, Memantine, Ifenprodil, Samidorphan, Ondelopran, ABT-436, SSR149415, Mifepristone, Ibudilast, Citicoline, Rimonabant, Surinabant, AM4113 and Gamma-hydroxybutyrate While some have shown promising results in the treatment of alcohol use disorder, others have disappointed and should be excluded from further investigation. "
|
2. | Body Weight (Weight, Body)
07/01/2012
- " The gain in body weight from baseline was reduced with surinabant 2.5 mg/day, 5 mg/day and 10 mg/day (0.75 kg [SE, 0.13], 0.53 kg [SE, 0.13], and 0.24 kg [SE, 0.13], respectively, versus 1.19 kg [SE, 0.13] for placebo; p for trend, < 0.001). " 01/01/2008
- " Adolescence (postnatal days 37-44) and/or post-adolescence (postnatal days 45-59) administration of Surinabant reduced body weight gain, as well as plasma glucose levels and triglycerides. "
|
3. | Binge Drinking
|
4. | Weight Gain
|
5. | Obesity
|
|
Related Drugs and Biologics
Related Therapies and Procedures